<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">HEV infected individuals can be treated with the antiviral ribavirin and for prophylaxis, a human vaccine, at least against HEV-1, was developed. However the efficacy against HEV-3 has still not been specifically tested and this vaccine has no approval outside of China [
 <xref ref-type="bibr" rid="CR59">59</xref>, 
 <xref ref-type="bibr" rid="CR60">60</xref>]. There is evidence that the number of reported HEV-3 infections increases not only due to greater awareness and better testing, but also due to a real increase in infection rates [
 <xref ref-type="bibr" rid="CR31">31</xref>, 
 <xref ref-type="bibr" rid="CR36">36</xref>, 
 <xref ref-type="bibr" rid="CR61">61</xref>]. However, in Switzerland the number of human infections declined [
 <xref ref-type="bibr" rid="CR40">40</xref>]. Within the specified region of the Swiss Bern canton, overall prevalence has declined over two decades from 30.3% in 1997/98 to 27.0% in 2006 and 22.3% in 2015/6 [
 <xref ref-type="bibr" rid="CR4">4</xref>].
</p>
